Corrigendum

Corrigendum to “Osteoporosis, Fractures, and Diabetes”

Peter Jackuliak and Juraj Payer

5th Department of Internal Medicine, Comenius University Faculty of Medicine and University Hospital in Bratislava, Ruzinovska 6, 826 06 Bratislava, Slovakia

Correspondence should be addressed to Peter Jackuliak; peter.jackuliak@gmail.com

Received 19 April 2017; Accepted 4 May 2017; Published 30 May 2017

Copyright © 2017 Peter Jackuliak and Juraj Payer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Osteoporosis, Fractures, and Diabetes” [1], there was an error regarding the FRAX® tool, which should be clarified as follows:

The article notes: “To partially answer this problem the current osteoporosis classification criteria drafted by the World Health Organization (WHO) are currently revised to include clinical risk factors (<http://www.shef.ac.uk/FRAX/>)” and “Recently, the fracture risk assessment (FRAX) algorithm has been developed by the WHO, which could assess the fracture risk of an individual even if BMD is not measured [109].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX® tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References

- [1] P. Jackuliak and J. Payer, “Osteoporosis, fractures, and diabetes,” *International Journal of Endocrinology*, vol. 2014, Article ID 820615, p. 10, 2014.
- [2] N. Ford, S. L. Norris, and S. R. Hill, “Clarifying WHO’s position on the FRAX® tool for fracture prediction,” *Bulletin of the World Health Organization*, vol. 94, no. 12, p. 862, 2016.